BD’s PosiFlush SafeScrub Study Completion: What Investors Should Watch Next

Becton, Dickinson and Co (BDX) announced an update on their ongoing clinical study.

The clinical study “An Investigational Study to Evaluate the Safety and Performance of the BD PosiFlush™ SafeScrub on Needleless Access Devices” tests a new flushing and disinfecting device from Becton, Dickinson and Co. The goal is to see if the product is safe to use and works as intended, which matters because it targets infections linked to intravenous catheters.

The trial compares the BD PosiFlush™ SafeScrub device with standard care. Standard care uses a prefilled saline syringe, the BD PosiFlush™ SP Syringe, plus an alcohol pad, while the new device combines steps to clean and flush needleless access devices more simply.

The study is interventional and randomized. Hospital units are assigned to either the new device or standard practice in parallel, with no blinding, and the main purpose is to collect practical performance and safety data rather than to test a drug.

The trial was first submitted in August 2024, marking the formal launch. The most recent update was posted on April 30, 2026, after the study had moved to completed status, which signals that data collection is done and analysis and reporting are the next steps.

For investors, this update supports BD’s efforts to grow in infection prevention and vascular access, areas where hospital demand is steady and pricing can be resilient. If final data show better safety or workflow benefits versus current practice, it could strengthen BD’s competitive position against peers in catheter care and support sentiment for BDX over the medium term.

The study has been completed and recently updated, with further details and any future results to be posted on the ClinicalTrials.gov portal.